Mixability Taste (Encapsulation recommended) Home Page Home Page Store Front Piracetam Piracetam (technically known as 2-oxo-pyrrolidone) was developed in the mid-1960's by UCB pharmaceutical company of Belgium.  It was originally used to treat motion sickness.   Between 1968 and 1972, however, there was an explosion of Piracetam research which uncovered its ability to facilitate learning, prevent amnesia induced by hypoxia and electroshock, and accelerate electroencephalograph return to normal in hypoxic animals.  By 1972 700 papers were published on Piracetam.) Yet already by 1972 Piracetam's pharmacologic uniqueness led C.E. Giurgea, UCB's principal Piracetam researcher and research coordinator, to formulate an entirely new category of supplements to describe Piracetam: the nootropics. (2)  According to Giurgea, nootropic drugs should have the following characteristics:  1) they should enhance learning and memory.  2) They should enhance the resistance of learned behaviors/memories to conditions which tend to disrupt them (e.g. electroconvulsive shock, hypoxia).  3)  They should protect the brain against various physical or chemical injuries (e.g. barbiturates, scopalamine).  5)  They should ''increase the efficacy of the tonic cortical/subcortical control mechanisms."  6)  They should lack the usual pharmacology of other psychotropic drugs (e.g. sedation, motor stimulation) and possess very few side effects and extremely low toxicity. (3)  Piracetam is the grandfather of all Nootropics. It stacks well with any of them. Acetyl-L-Carnitine, Alpha GPC, Choline Bitartrate, DMAE, GABA, L-Phenylalanine, L-Tyrosine & Tryptophan all works particularly well with Piracetam.

___________________________________________________________________